Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Autor:
Martijn P. Lolkema, Marco B. Polee, Olaf Loosveld, Paul Hamberg, Geert A. Cirkel, Stefan Sleijfer, Heinz-Josef Klümpen, Johanna E.A. Portielje, Emile E. Voest, Frank P. J. Peters, Vincent van der Noort, Gerard Groenewegen, Maartje Los, Maureen J.B. Aarts, Franchette W P J van den Berkmortel, Laurens V. Beerepoot, John B. A. G. Haanen, Metin Tascilar, M. Wouter Dercksen
Publikováno v:
JAMA oncology, 3(4), 501-508. American Medical Association
JAMA Oncology, 3(4), 501-508. American Medical Association
JAMA Oncology, 3(4), 501-508. American Medical Association
Importance To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective To test our hypothesis that an 8-week rotati
Autor:
Ajay K. Nooka, Jonathan L. Kaufman, Michael Luhua Wang, Andrew Yee, Noopur Raje, Paul G. Richardson, Jooeun Bae, Doris Peterkin
Publikováno v:
JAMA oncology. 4(12)
IMPORTANCE: Increasing evidence suggests the significance of the role of the immune system in the progression of smoldering multiple myeloma (SMM) to symptomatic multiple myeloma (MM). Boosting the immune system via vaccination in the earlier, asympt
Autor:
Ace J. Hatch, Jennifer H. Barrett, Sarah Brown, Andrew B. Nixon, Philip Quirke, Faye Elliott, Bart Jacobs, Susan D. Richman, Jenny F. Seligmann, Matthew T. Seymour, Herbert Hurwitz
Publikováno v:
JAMA oncology. 4(4)
Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit i
Autor:
Nicholas J. Short, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Xuelin Huang, Hagop M. Kantarjian, Tapan M. Kadia, Partow Kebriaei, Zeev Estrov, Jorge E. Cortes, David Marin, Koichi Takahashi, Marina Konopleva, Yogin B Patel, Deborah A. Thomas, Susan O'Brien, Nitin Jain, Koji Sasaki, Guillermo Garcia-Manero, Michael Rytting, Richard E. Champlin, Maria Khouri
Publikováno v:
JAMA oncology. 4(2)
Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective To evaluate the
Autor:
Benjamin R. Roman, Xin Pei, Eric J. Sherman, Jay O. Boyle, Jonathan E. Leeman, Praveen Venigalla, Nancy Y. Lee, Chiaojung J. Tsai, Sean McBride, Nadeem Riaz, Luc G. T. Morris, Lara Dunn, Eitan Lupovitch, Jin-Gao Li, Evangelia Katsoulakis, Zachary S. Zumsteg
Publikováno v:
JAMA oncology. 3(11)
Even though 15% to 50% of patients with head and neck squamous cell carcinoma (HNSCC) experience recurrence, relatively little is known regarding patterns of treatment failure and postrecurrence outcomes after chemoradiotherapy using modern radiation
Autor:
Dustin Smith, Stephen P. Hack, Florian Lordick, Maria Alsina, See Phan, David Cunningham, Yung-Jue Bang, Ian McCaffery, David S. Shames, Meng Chen, Manish A. Shah, Jean Marie Bruey
Publikováno v:
JAMA oncology. 3(5)
Importance Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report results of METGastric, a phase 3 trial of the MET inhibitor onartuzumab pl
Autor:
Funda Meric-Bernstam, Razelle Kurzrock, Vivek Subbiah, Rashmi Krishna Murthy, Kenneth R. Hess, Mariana Chavez-MacGregor, Stacy L. Moulder, Kimberly B. Koenig, James L. Murray, Nuhad K. Ibrahim, David S. Hong, Daniel D. Karp, Reva K. Basho, Shelley M. Herbrich, Vicente Valero, Thorunn Helgason, Filip Janku, Constance Albarracin, Michael Z. Gilcrease, Jennifer K. Litton
Publikováno v:
JAMA oncology. 3(4)
Importance Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to en
Autor:
Cesare Gridelli, Yuichiro Ohe, Jaafar Bennouna, Ashis Das-Gupta, Nick Thatcher, Margarita Donica, Francesco Grossi, Matt Truman, Konstantinos N. Syrigos, Javier de Castro Carpeño, Frank Griesinger, Anne-Marie C. Dingemans, Corey J. Langer, Vlatka Smoljanovic
Publikováno v:
JAMA Oncology, 4(12):183486. American Medical Association
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Importance Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond p
Autor:
Yeung-Chul Mun, James Larkin, Keith T. Flaherty, Edward McKenna, Brigitte Dréno, Qian Zhu, Antoni Ribas, Axel Hauschild, Paolo A. Ascierto, Karl D. Lewis, Grant A. McArthur
Publikováno v:
JAMA Oncology. 4:1382
Importance Prognostic models may provide insight into clinical trial results and inform the clinical management of patients withBRAFV600–mutated metastatic melanoma. Objective To identify subgroups with distinct survival outcomes based on clinical
Autor:
Begoña Bermejo, Milvia Zambetti, Isabel Alvarez, Vladimir Semiglazov, Andrew Redfern, Arrate Plazaola, Christian Dittrich, Antonio Antón, Rebecca Dent, Raffaella De Fato, Luca Gianni, Lourdes Calvo, Mauro Mansutti, Pinuccia Valagussa, Domenico Magazzu, Jose Ignacio Chacon, Ignacio Tusquets, Marc Thill, Giancarlo Bisagni, Serafin Morales, Arlene Chan
Publikováno v:
JAMA Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Importance Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not redu